The following side effects are expected to occur with the use of minocycline foam and become less severe with ongoing treatment. Contact your doctor if these symptoms are severe and/or do not go away:
How Common (based on clinical studies)
| Itching | Up to 56.16% of all users |
| Skin peeling | Up to 55.86% of all users |
| Dryness of skin | Up to 54.33% of all users |
| Hyperpigmentation | Up to 52.66% of all users |
| Erythema | Up to 52.51% of all users |
If you experience any of the following side effects, stop using minocycline foam immediately and contact your doctor or get emergency medical care right away:
- Rash that occurs alongside fever and swollen glands in the neck or elsewhere
- Trouble breathing or swallowing
- Reappearance of sore throat, fever, and/or other symptoms of infection
- Swelling of the eyes, lips, tongue, throat, or face
- A sudden appearance of swelling and rash (known as hives)
- Chest pain
Minocycline foam may also cause other side effects that are not mentioned here. Contact your doctor if you experience any other troublesome symptoms when using minocycline foam.
References
- DailyMed (2023). Sarecycline. [online] Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fd99a72-047f-4fd9-93c1-712599fd3870. [Accessed 08 Oct. 2023]
- Raoof TJ, Hooper D, Moore A, Zaiac M, Sullivan T, Kircik L, Lain E, Jankicevic J, Stuart I. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study. Journal of the American Academy of Dermatology. 82(4), 832-837 (2020).
- Stein Gold L, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart I. Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4% Minocycline Foam for Moderate-to-Severe Acne Vulgaris. Journal of Clinical and Aesthetic Dermatology. 12(10), 16-23 (2019).
- Gold LS, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart IA. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies. Journal of the American Academy of Dermatology. 80(1), 168-177 (2019).